Add to ORKG359 Background: There are no established biomarkers predicting outcome of SUN treatment in mRCC.status: publishe
Background: Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently treated ...
Aims: Patients with metastatic or inoperable kidney cancer with positive biomarkers of vascular endo...
Purpose: The objective of this study was to identify genetic polymorphisms related to the pharmacoki...
Altres ajuts : SOGUG-2011-05Several potential predictive markers of efficacy of targeted agents in p...
Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from ...
Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used...
BACKGROUND: Several drugs are available to treat metastatic renal-cell carcinoma (MRCC), and predic...
To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in metastatic ren...
Sunitinib has been approved by FDA in 2006 and became the first-line treatment for pat...
International audienceFrom 10% to 26% of patients with metastatic renal cell carcinoma (mRCC) experi...
Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal...
WOS: 000382525900009PubMed ID: 27358594Aim of the study: Sunitinib-related side effects may develop ...
BACKGROUND: The present retrospective, longitudinal cohort study assessed the association between th...
Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinom...
Item does not contain fulltextOBJECTIVE: To evaluate the effect of cytoreductive nephrectomy (CN) on...
Background: Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently treated ...
Aims: Patients with metastatic or inoperable kidney cancer with positive biomarkers of vascular endo...
Purpose: The objective of this study was to identify genetic polymorphisms related to the pharmacoki...
Altres ajuts : SOGUG-2011-05Several potential predictive markers of efficacy of targeted agents in p...
Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from ...
Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used...
BACKGROUND: Several drugs are available to treat metastatic renal-cell carcinoma (MRCC), and predic...
To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in metastatic ren...
Sunitinib has been approved by FDA in 2006 and became the first-line treatment for pat...
International audienceFrom 10% to 26% of patients with metastatic renal cell carcinoma (mRCC) experi...
Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal...
WOS: 000382525900009PubMed ID: 27358594Aim of the study: Sunitinib-related side effects may develop ...
BACKGROUND: The present retrospective, longitudinal cohort study assessed the association between th...
Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinom...
Item does not contain fulltextOBJECTIVE: To evaluate the effect of cytoreductive nephrectomy (CN) on...
Background: Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently treated ...
Aims: Patients with metastatic or inoperable kidney cancer with positive biomarkers of vascular endo...
Purpose: The objective of this study was to identify genetic polymorphisms related to the pharmacoki...